Meywald W, Maass L, Verho M, Rangoonwala B
Pharmatherapeutica. 1985;4(6):356-66.
A single-blind study was carried out in 22 out-patients with mild to moderate hypertension to investigate the effects of piretanide capsules on systolic and diastolic blood pressure during standardized ergometric and isometric exercise. After a 4-week run-in period on placebo, patients received 1 capsule (6 mg) once daily for 6 weeks. If diastolic pressure was normalized (less than 95 mmHg), this dosage was continued for a further 6 weeks; patients whose blood pressure remained high after the initial 6 weeks received 1 capsule twice daily for a further 6 weeks. Significant reductions in blood pressure (9.2% for systolic, 14.6% for diastolic) were measured after 12-weeks' treatment during maximum ergometric work load exercise; during isometric exercise the reductions were 8.1% and 12.4%, respectively. The pulse-pressure product (a parameter indicating myocardial oxygen consumption), calculated for maximum ergometric exercise, was also significantly reduced by 8.8% after 12-weeks' active drug treatment. Serum levels of potassium, creatinine, urea, uric acid and cholesterol showed no clinically relevant changes during treatment. Side-effects definitely or probably associated with piretanide were observed in 13 patients. These, however, were generally mild and did not lead to interruption of piretanide treatment. Transient polyuria was reported by 5 patients during the first 2 weeks of active drug treatment; only 3 patients reported mild polyuria after 12 weeks of active drug treatment. The beneficial effect of piretanide especially on systolic blood pressure during exercise was in marked contrast effect of piretanide especially on systolic blood pressure during exercise was in marked contrast to the lack of such an effect reported during treatment with thiazide and other thiazide-like diuretics.
对22例轻至中度高血压门诊患者进行了一项单盲研究,以调查吡咯他尼胶囊在标准化测力和等长运动期间对收缩压和舒张压的影响。在服用安慰剂的4周导入期后,患者每天服用1粒胶囊(6毫克),持续6周。如果舒张压恢复正常(低于95毫米汞柱),则该剂量继续服用6周;在最初6周后血压仍高的患者,再服用6周,每天2次,每次1粒胶囊。在最大测力工作负荷运动的12周治疗后,测量到血压显著降低(收缩压降低9.2%,舒张压降低14.6%);在等长运动期间,降低幅度分别为8.1%和12.4%。在最大测力运动时计算的脉压乘积(一个指示心肌耗氧量的参数),在12周的活性药物治疗后也显著降低了8.8%。治疗期间,血清钾、肌酐、尿素、尿酸和胆固醇水平未出现临床相关变化。13例患者观察到明确或可能与吡咯他尼相关的副作用。然而,这些副作用一般较轻,并未导致吡咯他尼治疗中断。5例患者在活性药物治疗的前2周报告有短暂多尿;在活性药物治疗12周后,只有3例患者报告有轻度多尿。吡咯他尼对运动期间收缩压的有益作用与噻嗪类和其他噻嗪样利尿剂治疗期间报告的缺乏这种作用形成明显对比。